Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals

AIDS Research and Human Retroviruses

Volumn 23, Issue 11, 2007, Pages 1348-1353

  Vermeulen, Joost N ^a,b,e   Prins, Jan M ^b   Bunnik, Evelien ^b   Hack, C Erik ^b,d   Jurriaans, Suzanne ^b   Miedema, Frank ^b,c   Lange, Joep M A ^a,b   Schuitemaker, Hanneke ^b  

^a IATEC   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d CRUCELL HOLLAND BV   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; KI 67 ANTIGEN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL LOSS; CELL PROLIFERATION; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TURNOVER TIME; BIOSYNTHESIS; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; MIDDLE AGED; VIRUS LOAD;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KI-67 ANTIGEN; LYMPHOCYTE ACTIVATION; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 38449096502     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0210     Document Type: Article

References (32)

1. Palella FJJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853- 860.
2. Detels R, Munoz A, McFarlane G, et al.: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280(17):1497-1503.
3. Lee LM, Karon JM, Selik R, Neal JJ, and Fleming PL: Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001;285(10):1308-1315.
4. Mocroft A, Ledergerber B, Katlama C, et al.: Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362(9377):22-29.
5. Embretson J, Zupancic M, Beneke J, et al.: Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc Natl Acad Sci USA 1993;90(1):357-361.
6. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387(6629):183-188.
7. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200(6):749-759.
8. Hazenberg MD, Hamann D, Schuitemaker H, and Miedema F: T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock. Nat Immunol 2000;1(4):285-289.
9. Swingler S, Mann A, Jacque J, et al.: HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999;5(9):997-103.
10. Sprent J: Lifespans of naive, memory and effector lymphocytes. Curr Opin Immunol 1993;5(3):433-438.
11. Mohri H, Perelson AS, Tung K, et al.: Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001;194(9):1277-1287.
12. Hazenberg MD, Otto SA, Benthem BHB, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17(13):1881-1888.
13. Rutschmann OT, Opravil M, Iten A, et al.: A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12(8):F71-F77.
14. Kaplan G, Thomas S, Fierer DS, et al.: Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000;16(14):1345-1355.
15. Rizzardi GP, Vaccarezza M, Capiluppi B, et al.: Cyclosporin A in combination with HAART in primary HIV-1 infection. J Biol Regul Homeost Agents 2000;14(1):79-81.
16. Kazatchkine MD and Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345(10):747-755.
17. Aukrust P, Hestdal K, Lien E, et al.: Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection. J Infect Dis 1997;176(4):913-923.
18. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133(4):1710-1715.
19. Baars PA, Maurice MM, Rep M, Hooibrink B, and Van Lier RA: Heterogeneity of the circulating human CD4+ T cell population. Further evidence that the CD4+CD45RA-CD27- T cell subset contains specialized primed T cells. J Immunol 1995;154(1):17-25.
20. Hamann D, Baars PA, Rep MH, et al.: Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186(9):1407-1418.
21. Van Lier RA, Boot JH, Verhoeven AJ, et al.: Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3. J Immunol 1987;139(9):2873-2879.
22. Van Lier RA, Brouwer M, and Aarden LA: Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur J Immunol 1988;18(1):167-172.
23. Jansen PM, van der Pouw Kraan TC, de Jong IW, et al.: Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: Relation to plasma levels of interleukin-10 and interferon-gamma. Blood 1996;87(12):5144-5151.
24. Hack CE, Paardekooper J, Smeenk RJ, et al.: Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies. J Immunol 1988;141(5):1602-1609.
25. Wolbink GJ, Bollen J, Baars JW, et al.: Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993;163(1):67-76.
26. Wolbink GJ, Brouwer MC, Buysmann S, Ten Berge IJ, and Hack CE: CRP-mediated activation of complement in vivo: Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996;157(1):473-479.
27. Teeling JL, de Groot ER, Eerenberg AJ, et al.: Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Clin Exp Immunol 1998;114(2):264-270.
28. Hazenberg MD, Otto SA, Cohen Stuart JW, et al.: Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000;6(9):1036-1042.
29. Pakker NG, Notermans DW, de Boer RJ, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 1998;4(2):208-214.
30. Yu Z and Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340(3):227-228.
31. Bleeker WK, Teeling JL, and Hack CE: Accelerated autoantibody clearance by intravenous immunoglobulin therapy: Studies in experimental models to determine the magnitude and time course of the effect. Blood 2001;98(10):3136-3142.
32. Hazenberg MD, Stuart JW, Otto SA, et al.: T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000;95(1):249-255.